FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3212629411> ?p ?o ?g. }

• W3212629411 endingPage "620" @default.
• W3212629411 startingPage "620" @default.
• W3212629411 abstract "Abstract Methods : This multicentric retrospective study aimed to evaluate the efficacy and the safety of the combination of BBV in patients with non-cutaneous R/R PTCL among 21 LYSA centers in France and Belgium. The primary objective was to evaluate the best overall response rate (ORR) (complete response (CR) and partial response (PR)). Secondary objectives were progression free survival (PFS), overall survival (OS), duration of response (DoR), impact of transplantation on outcome, and safety. Patients treated between January 2013 and October 2020 were reviewed and all the data were collected through an electronic questionnaire sent to all the physicians. Results : Eighty two patients with R/R PTCL (40 angioimmunoblastic lymphoma (AITL), 2 T-cell lymphoma with TFH phenotype ,13 PTCL not otherwise specified (PTCL NOS), 5 Alk+ anaplastic large cell lymphoma (ALCL), 17 Alk- ALCL, , 1 Extranodal NK-/T-cell lymphoma, 3 Enteropathy-associated T-cell lymphoma (EATL), 1 subcutaneous panniculitis) were included. Median age at beginning of BBV was 60 years, most of patients were male (61%), had advanced stage (88%) and an IPI ≥ 2 (79%). Half of patients were refractory to their last treatment. Median number of prior regimens was 1 (range 1 to 6). The best ORR was 71%, with 51% of patients in CR. In multivariable analysis, only the relapse status after the last regimen (relapse vs refractory) was associated with ORR, relapsed patients having a better ORR (83% vs 57% in refractory patients, p=.014, OR=3.70 (95%CI:1.3-10.5)). Median DoR was 15.4 months in patients with CR but differed significantly whether patients were transplanted or not (Not reached vs 8.4 months, p=.0055). Twenty-two patients (30% of patients ≤ 70 years of age) were transplanted (6 autologous and 16 allogenic). With a median follow-up of 9 months, the median PFS and OS were 8.3 and 26.3 months respectively. In multivariable analysis, only 2 factors had a significant impact on PFS and OS: best response (CR/PR vs SD/PD with a median PFS of 17.4 vs 1.9 months, p&lt;.0001, and a median OS Not Reached vs 5,9 months, p&lt;.0001) and transplantation (for patients in CR, median PFS was Not Reached in transplanted patients vs 13.1 months; p=.0410, and median OS was Not Reached vs 34, 6 months; p=.0304) (Fig1). Histological subgroups was also significantly associated with PFS (p=.012) but not with OS (p=.26) in multivariable analysis. Patients with PTCL NOS/Other subtypes had worse PFS than patients with TFH subtypes (HR=2.89 (95%CI: 1.4-5.8), p=.0029). Interestingly the CD30 status (positive vs negative) had no impact on ORR or survival. Fifty-nine percent of patients experienced a grade 3 to 4 adverse event which was mainly hematologic toxicity. Treatment had to be stopped in 11% of patients. Conclusion: To the best of our knowledge, this is the first study reporting on the combination of BBV in the treatment of R/R PTCL in such a large cohort. The results are very encouraging with a high response rate, long DoR in responding patients and a very good outcome. Furthermore, patients in CR who are eligible for transplant have the best outcome, making this combination a good candidate as salvage therapy before transplant consolidation in these high-risk lymphomas with limited treatment options. Figure 1 Figure 1. Disclosures Bouabdallah: Kite/Gilead: Consultancy, Honoraria; Takeda: Consultancy, Honoraria; Roche: Consultancy, Honoraria. Herbaux: Takeda: Honoraria, Research Funding; Janssen: Honoraria; Roche: Honoraria; Abbvie: Honoraria, Research Funding. Brice: MSD: Research Funding; Amgen: Other: Travel/accommodations/expenses; Roche: Other: Travel/accommodations/expenses; Takeda: Research Funding. Sibon: Abbvie: Consultancy; Janssen: Consultancy; Roche: Consultancy; iQone: Consultancy; Takeda: Consultancy. Laribi: AstraZeneca: Other: Personal Fees; AbbVie: Other: Personal Fees, Research Funding; IQONE: Other: Personal Fees; Astellas Phama, Inc.: Other: Personal Fees; BeiGene: Other: Personal Fees; Takeda: Other: Personal Fees, Research Funding; Novartis: Other: Personal Fees, Research Funding; Le Mans Hospital: Research Funding; Jansen: Research Funding. Damaj: roche: Consultancy, Honoraria; takeda: Consultancy, Honoraria. OffLabel Disclosure: Brentuximab Vedotin and Bendamustine" @default.
• W3212629411 created "2021-11-22" @default.
• W3212629411 creator A5012900514 @default.
• W3212629411 creator A5013796104 @default.
• W3212629411 creator A5013996935 @default.
• W3212629411 creator A5014686259 @default.
• W3212629411 creator A5015230787 @default.
• W3212629411 creator A5020551031 @default.
• W3212629411 creator A5024295989 @default.
• W3212629411 creator A5025168447 @default.
• W3212629411 creator A5029209393 @default.
• W3212629411 creator A5031098581 @default.
• W3212629411 creator A5038631933 @default.
• W3212629411 creator A5040444445 @default.
• W3212629411 creator A5045486705 @default.
• W3212629411 creator A5052071966 @default.
• W3212629411 creator A5055439790 @default.
• W3212629411 creator A5056514957 @default.
• W3212629411 creator A5058751095 @default.
• W3212629411 creator A5062422990 @default.
• W3212629411 creator A5068021241 @default.
• W3212629411 creator A5068452218 @default.
• W3212629411 creator A5069918654 @default.
• W3212629411 creator A5071546755 @default.
• W3212629411 creator A5075792404 @default.
• W3212629411 creator A5076293825 @default.
• W3212629411 creator A5080661528 @default.
• W3212629411 creator A5085150178 @default.
• W3212629411 creator A5088395604 @default.
• W3212629411 creator A5089493611 @default.
• W3212629411 date "2021-11-05" @default.
• W3212629411 modified "2023-10-01" @default.
• W3212629411 title "Salvage Therapy with Brentuximab-Vedotin and Bendamustine for Patients with Relapsed/Refractory T Cell Lymphoma. a Multicenter and Retrospective Study" @default.
• W3212629411 doi "https://doi.org/10.1182/blood-2021-150953" @default.
• W3212629411 hasPublicationYear "2021" @default.
• W3212629411 type Work @default.
• W3212629411 sameAs 3212629411 @default.
• W3212629411 citedByCount "1" @default.
• W3212629411 countsByYear W32126294112022 @default.
• W3212629411 crossrefType "journal-article" @default.
• W3212629411 hasAuthorship W3212629411A5012900514 @default.
• W3212629411 hasAuthorship W3212629411A5013796104 @default.
• W3212629411 hasAuthorship W3212629411A5013996935 @default.
• W3212629411 hasAuthorship W3212629411A5014686259 @default.
• W3212629411 hasAuthorship W3212629411A5015230787 @default.
• W3212629411 hasAuthorship W3212629411A5020551031 @default.
• W3212629411 hasAuthorship W3212629411A5024295989 @default.
• W3212629411 hasAuthorship W3212629411A5025168447 @default.
• W3212629411 hasAuthorship W3212629411A5029209393 @default.
• W3212629411 hasAuthorship W3212629411A5031098581 @default.
• W3212629411 hasAuthorship W3212629411A5038631933 @default.
• W3212629411 hasAuthorship W3212629411A5040444445 @default.
• W3212629411 hasAuthorship W3212629411A5045486705 @default.
• W3212629411 hasAuthorship W3212629411A5052071966 @default.
• W3212629411 hasAuthorship W3212629411A5055439790 @default.
• W3212629411 hasAuthorship W3212629411A5056514957 @default.
• W3212629411 hasAuthorship W3212629411A5058751095 @default.
• W3212629411 hasAuthorship W3212629411A5062422990 @default.
• W3212629411 hasAuthorship W3212629411A5068021241 @default.
• W3212629411 hasAuthorship W3212629411A5068452218 @default.
• W3212629411 hasAuthorship W3212629411A5069918654 @default.
• W3212629411 hasAuthorship W3212629411A5071546755 @default.
• W3212629411 hasAuthorship W3212629411A5075792404 @default.
• W3212629411 hasAuthorship W3212629411A5076293825 @default.
• W3212629411 hasAuthorship W3212629411A5080661528 @default.
• W3212629411 hasAuthorship W3212629411A5085150178 @default.
• W3212629411 hasAuthorship W3212629411A5088395604 @default.
• W3212629411 hasAuthorship W3212629411A5089493611 @default.
• W3212629411 hasBestOaLocation W32126294111 @default.
• W3212629411 hasConcept C121332964 @default.
• W3212629411 hasConcept C126322002 @default.
• W3212629411 hasConcept C141071460 @default.
• W3212629411 hasConcept C142424586 @default.
• W3212629411 hasConcept C143998085 @default.
• W3212629411 hasConcept C2776694085 @default.
• W3212629411 hasConcept C2777872185 @default.
• W3212629411 hasConcept C2778191690 @default.
• W3212629411 hasConcept C2778336483 @default.
• W3212629411 hasConcept C2779338263 @default.
• W3212629411 hasConcept C2780739268 @default.
• W3212629411 hasConcept C2780775027 @default.
• W3212629411 hasConcept C2781413609 @default.
• W3212629411 hasConcept C2911091166 @default.
• W3212629411 hasConcept C70905583 @default.
• W3212629411 hasConcept C71924100 @default.
• W3212629411 hasConcept C87355193 @default.
• W3212629411 hasConcept C90924648 @default.
• W3212629411 hasConceptScore W3212629411C121332964 @default.
• W3212629411 hasConceptScore W3212629411C126322002 @default.
• W3212629411 hasConceptScore W3212629411C141071460 @default.
• W3212629411 hasConceptScore W3212629411C142424586 @default.
• W3212629411 hasConceptScore W3212629411C143998085 @default.
• W3212629411 hasConceptScore W3212629411C2776694085 @default.
• W3212629411 hasConceptScore W3212629411C2777872185 @default.
• W3212629411 hasConceptScore W3212629411C2778191690 @default.
• W3212629411 hasConceptScore W3212629411C2778336483 @default.
• W3212629411 hasConceptScore W3212629411C2779338263 @default.
• W3212629411 hasConceptScore W3212629411C2780739268 @default.

• next